Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, MacPherson I, Nathan M, Verrill M, Eva J, Doody C, Chowdhury R September 16, 2021 ESMO 2021 Breast Cancer

A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program

View Presentation
Poster
Solomon BJ, Mok T, Hayashi H, Bearz A, Penkov K, Wu Y-L, Arrieta O, Calella AM, Peltz G, Polli A, Thurm H, Bauer TM September 16, 2021 ESMO 2021 Lung Cancer

Dose modification for the management of central nervous sytem adverse events in the Phase 3 CROWN study of lorlatinib in non-small cell lung cancer

View Presentation View Abstract Plain Language Summary
Poster
Rugo HS, Im S-A, Joy AA, Yaroslav S, Walshe JM, Sleckman B, Loi S, Puyana Theall K, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Dieras V September 16, 2021 ESMO 2021 Breast Cancer

Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC): post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)

View Presentation View Abstract Plain Language Summary
Poster
Saltzstein DR, Shore ND, Saad F, George DJ, Cookson MS, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Walling J, Tombal B September 16, 2021 ESMO 2021 Prostate Cancer

Efficacy and Safety of Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Clinical Subgroup Analysis from the Phase 3 HERO Study 

View Presentation View Abstract Plain Language Summary
Poster
Zhou Q, Kim HR, Soo RA,   Chang G-C, Chiu C-H, Hayashi H, Kim S-W, Teraoka S, Goto Y, Zhou J, Lee V H-F, Han B, Ho JCM, Kim D-W, Lin C-C, Lu S, Polli A, Calella AM, Mok T, Wu Y-L September 16, 2021 ESMO 2021 Lung Cancer

First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN

View Presentation View Abstract Plain Language Summary
Poster
Chang R, Cha A, Law E, Kurosky SK, Chen X, Fang H, Xie J September 16, 2021 ESMO 2021 Breast Cancer

First-Line Treatments and Clinical Outcomes for Hormone Receptor-Positive , Human Epidermal Growth Factor 2-Positive  Advanced or Metastatic Breast Cancer: A Systematic Literature Review 

View Presentation View Abstract Plain Language Summary
Poster
Bossi A, Shore ND, Tutrone R, Cookson MS, George DJ, Saltzstein DR,  Brown B, Selby B, Lu S, Walling J, Tombal B September 16, 2021 ESMO 2021 Prostate Cancer

Geographical Assessment of Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study vs Leuprolide in Men with Advanced Prostate Cancer (APC)

View Presentation View Abstract Plain Language Summary
Poster
Martin M, Rugo HS, Hurvitz SA, Ettl J, Roche H, Lee K-H, Goodwin A, Usari T, Lanzalone S, Guenzel C, Blum JL, Litton JK September 16, 2021 ESMO 2021 Breast Cancer

Outcomes of Patients (pts) who had Received Prior Platinum (PP) Therapy in the Phase 3 EMBRACA Trial of Talazoparib (TALA) vs Physician’s Choice of Chemotherapy (PCT) in Patients with Germline BRCA1/2 Mutated (gBRCA1/2mut) Advanced Breast Cancer (ABC)

View Presentation View Abstract Plain Language Summary
Poster
Valachis A, Lindman H, Fues Wahl H, Lauppe R, Lilja M, Nyqvist D, Jakobsson M September 16, 2021 ESMO 2021 Breast Cancer

Palbociciclib dose patterns in Swedish patients with metastatic breast cancer: Evidence from the SIRI study

View Presentation
Poster
Rugo HS, Niyazov A, Bhattacharyya H,    Arondekar B, Hurvitz SA  September 16, 2021 ESMO 2021 Breast Cancer

Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2– advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2m): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial

View Presentation View Abstract Plain Language Summary